title: Improvement in short-term visual memory by weak electromagnetic fields in Parkinson's disease.
abstract: Neuropsychological studies have demonstrated that Parkinson's disease (PD) is associated with various cognitive deficits ultimately leading in about 30% of patients to the development of dementia. These studies have demonstrated also a greater decrement of right hemispheric functions with visuospatial deficits occurring in up to 90% of PD patients. The Rey-Osterrieth Complex Figure (ROCF) Test has been employed in the assessment of right hemispheric functions and particularly for the evaluation of visuoconstructive abilities and short-term visual memory. I have demonstrated recently that external application of electromagnetic fields (EMFs) in the picotesla (pT) range intensity is an effective nonpharmacological modality in the management of the motor and cognitive deficits of Parkinsonism. In the present communication I present 3 fully medicated nondemented PD patients (mean age: 68 +/- 8.1 yrs; mean duration of illness: 9.0 +/- 4.0 yrs; mean disability on the Hoehn and Yahr scale: 3) who were tested on the ROCF Test before and after a series of treatments with EMFs. In response to the administration of EMFs the group demonstrated a mean of 23.1 +/- 13.6% improved performance on copy of the ROCF and a 39.3 +/- 13.4% improvement of short-term recall of the ROCF. These findings demonstrate that treatment with pT EMFs improves deficits in visuospatial functions and visual memory in Parkinsonism which usually remain unaffected during standard treatment with dopaminergic pharmacotherapy.
authors.affiliation: NeuroCommunication Research Laboratories, Danbury, CT 06811, USA.
authors.forename: R
authors.initials: R
authors.lastname: Sandyk
mesh_terms: D000368:Aged; D003072:Cognition Disorders / Q000175:diagnosis / Q000209:etiology; D055590:Electromagnetic Phenomena; D007839:Functional Laterality; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000209:etiology*; D011939:Mental Recall; D008875:Middle Aged; D009483:Neuropsychological Tests; D010296:Parietal Lobe / Q000503:physiopathology; D010300:Parkinson Disease / Q000150:complications* / Q000503:physiopathology / Q000628:therapy*; D010870:Pineal Gland / Q000378:metabolism; D016896:Treatment Outcome